Adverse drug reaction patterns of GLP‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database
Diabetes Obesity and Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 2, 2025
This
study
aims
to
compare
adverse
drug
reaction
patterns
of
liraglutide,
semaglutide
and
tirzepatide-glucagon-like
peptide-1
receptor
agonists
(GLP-1
RAs)
approved
for
anti-obesity
medications-to
evaluate
their
real-world
safety.
disproportionality
analysis
utilized
a
case-control
design
with
VigiBase.
The
focused
on
reports
events
associated
tirzepatide,
selected
based
warnings
in
the
US
Food
Drug
Administration
approval
labels
each
drug.
Data
were
restructured
using
unique
identifiers
differentiate
individuals
affected
by
reactions.
Multivariable
logistic
regression
models
estimated
adjusted
reporting
odds
ratios
(aRORs)
95%
confidence
intervals
(CIs)
assess
association
between
various
GLP-1
RAs,
adjusting
age,
sex,
region,
reporter
qualification,
year
concomitant
medication.
information
component
(IC)
was
analysed,
signals
reactions
considered
significant
only
when
both
aROR
IC
statistically
significant.
Our
targeted
included
24
725
21
454
11
538
tirzepatide.
Tirzepatide
had
fewer
compared
other
two
drugs,
its
pharmacovigilance
strength
lowest.
Semaglutide,
however,
significantly
several
unusual
events,
including
suicidal
ideation
behaviour
(IC,
1.53
[IC025,
1.28];
aROR,
2.52
[95%
CI,
2.18-2.93]),
hair
loss
0.78
0.63];
1.42
1.30-1.55])
vision
1.27
1.13];
1.80
1.66-1.97]).
findings
emphasize
need
cautious
prescribing
further
research
ensure
safe
use
these
medications.
Language: Английский
Glucagon-like peptide-1 receptor agonists in peri-operative care
European Journal of Anaesthesiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 2, 2024
With
the
growing
use
of
glucagon-like-peptide-1
(GLP-1)
receptor
(GLP-1R)
agonists
as
anti-obesity
medication
it
is
becoming
increasingly
important
to
examine
its
consequences
in
peri-operative
period.
GLP-1R
are
known
for
their
glucose-lowering
and
gastroparetic
effects
which
latter
causes
some
safety
concerns
regarding
induction
anaesthesia,
more
specifically
risk
pulmonary
aspiration.
This
article
gathers
available
evidence
on
this
subject
addition
already
established
guidelines.
Current
makes
us
assume
there
indeed
an
increased
level
gastroparesis,
but
no
studies
date
with
a
presumed
elevated
Future
perspectives
should
focus
actual
aspiration
possible
implementation
ultrasound
preoperative
assessment.
Language: Английский